Peptide Plug

Age Verification

Peptide Plug is a research and organization tool intended for adults 18 years of age or older. By continuing, you confirm you are at least 18.

Reference only · Not medical advice · For adults 18+ · No dosing information is published here
Peptide Plug
HomeResearchEducationToolsGuidesCompareAboutOpen the App
Home/Research library/Exemestane
Aromatase Inhibitors

Exemestane — reference

Steroidal (irreversible) aromatase inhibitor for hormone-receptor-positive breast cancer.

Regulatory statusFDA-Approved (labeled use)
Published half-life~24 hours
Evidence levelFDA label
CategoryAromatase Inhibitors

Regulatory status

FDA-Approved (labeled use). FDA-approved for breast cancer. Use in men is off-label.

Reported cautions

⚠ Worth knowing. Binds the aromatase enzyme irreversibly, so effects persist until new enzyme is synthesised — it cannot be dialled back as quickly as the non-steroidal inhibitors.

Pharmacokinetics

Published figures give an elimination half-life of ~24 hours. FDA label (Aromasin).

This figure is tagged FDA label in our evidence system. This figure appears in an approved product's prescribing information, which is the strongest tier in our system — a regulator-reviewed number for a specific approved product. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.

Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →

What Peptide Plug does and does not publish

This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.

Frequently asked

Is Exemestane FDA-approved?
FDA-Approved (labeled use). FDA-approved for breast cancer. Use in men is off-label.
What is the half-life of Exemestane?
Published figures give ~24 hours. FDA label (Aromasin).
How reliable is that half-life figure?
It is tagged “FDA label” in our system. This figure appears in an approved product's prescribing information, which is the strongest tier in our system — a regulator-reviewed number for a specific approved product.
What cautions are associated with Exemestane?
Binds the aromatase enzyme irreversibly, so effects persist until new enzyme is synthesised — it cannot be dialled back as quickly as the non-steroidal inhibitors.
Does Peptide Plug publish dosing for Exemestane?
No. This library publishes regulatory status, general context and pharmacokinetics only. Dose, frequency and cycle information is deliberately absent from these public pages — those are clinical decisions, not reference data.
Does Peptide Plug sell Exemestane?
No. We do not sell, supply, source or link to vendors for any compound, and we have no affiliate arrangements with suppliers. Peptide Plug is a tracking and calculation tool.

Related tools

Free, no account required.

TRT Dose Calculator
Weekly target split across injections.
Free Testosterone Calculator
Vermeulen estimate from labs.
Half-Life Visualizer
Estimated rise-and-fall curve between doses.
Reconstitution Calculator
Vial math including blend support.
Medication Storage Calculator
Discard windows from published guidance.
Half-Life Data Table
All 86 compounds with evidence tags.
Reference information, not medical advice. This page describes regulatory status and published pharmacokinetics. It does not tell you whether to use this compound, how much to use, how often, or whether it is safe for you. Peptide Plug does not sell, supply or source any compound. Those decisions belong to you and a licensed clinician.

Part of the Peptide Plug research library · How we source our figures